play an increasingly critical role in early clinical development, particularly in Phase 1 trials where mechanistic insight and early signal detection are vital. They help characterize drug activity, confirm biological effects, and sometimes predict patient response. A well-planned biomarker strategy can accelerate decision-making, improve patient selection, and reduce risk in later stages. This article explores how to differentiate and deploy exploratory versus predictive biomarkers in Phase 1 trials, supported by regulatory guidance and real-world examples.

Why Biomarkers Matter in Phase 1

• Establish pharmacodynamic (PD) proof of concept
• Support dose rationale and escalation decisions
• Identify responders or resistance markers
• Reduce development failure by validating mechanism early

Types of Biomarkers in Early Trials

1. Exploratory Biomarkers

• Used to understand mechanism of action (MoA), PK/PD, and biological activity
• Not validated or necessarily linked to outcome
• Examples: cytokine levels, pathway activation (e.g., pERK), circulating tumor DNA (ctDNA)

2. Predictive Biomarkers

• Indicate likelihood of response to treatment
• Often associated with target expression or mutation
• Examples: EGFR mutation (for TKIs), PD-L1 expression (for checkpoint inhibitors)

3. Safety Biomarkers

• Indicate potential toxicity or adverse reactions
• Examples: Troponin for cardiac toxicity, ALT/AST for hepatotoxicity

Where Biomarkers Fit in the Phase 1 Trial Design

• Pre-dose baseline levels (to assess change)
• Time-matched PK and PD assessments
• Serial sampling to track response and identify optimal timepoints

Integrating Biomarkers into Study Objectives

• Exploratory endpoints should be included in protocol and SAP
• Label as “hypothesis-generating” to manage regulatory expectations
• Biomarker collection should be feasible, ethical, and justified

Analytical Techniques and Sample Types

• Blood-based: plasma, serum, whole blood (e.g., cytokines, CRP, cfDNA)
• Tissue-based: biopsies for IHC, NGS, RNAseq
• Urine/saliva/exhaled breath: non-invasive and useful for early markers

Regulatory Considerations

FDA

• Encourages biomarker use for dose selection and MoA confirmation
• Distinguishes between “fit-for-purpose” vs. “validated” biomarkers
• Submit biomarker strategy in pre-IND meeting for high-risk agents

EMA

• Expects exploratory biomarkers to be clearly labeled in protocol and IB
• Supports predictive biomarker inclusion if linked to stratification strategy

CDSCO

• Permits collection of exploratory biomarker samples in FIH trials
• Requires ethics committee approval for optional biopsy or genetic analysis

Challenges in Biomarker Strategy

• Variability in sample handling can obscure signal
• Limited sample size in Phase 1 may not power statistical correlations
• Assay development lag behind protocol timelines

Case Example

In a Phase 1 trial of a JAK inhibitor, researchers included pSTAT3 as an exploratory PD marker in whole blood. A consistent drop in pSTAT3 levels 2 hours post-dose was observed, confirming target engagement. Though exploratory, this signal helped support dose selection for Phase 2, even before efficacy data were available.

Best Practices

• Engage translational science team early in protocol design
• Define sample collection, storage, and analysis plans clearly
• Use validated assays where possible and pilot new ones
• Align with regulatory expectations and ethical guidelines
• Interpret exploratory results with caution—validate in later trials